How should we assess the efficacy of new treatments in rare tumours?
Traditional approaches to generating clinical evidence rely on recruiting large numbers of patients into trials. Paolo Bruzzi reflects on the challenges of designing and analysing clinical trials in rare cancers, and reviews the potential for [more]